Influence of primary care antibiotic prescribing on incidence rates of bacteria in hospitalised patients
Published in: ESCP Conference in Clinical Pharmacy 24-27 October 2018
Nov 29, 2018
The 47th ESCP symposium on clinical pharmacy Personalised pharmacy care. 24–26 October 2018, Belfast, Northern Ireland. Influence of primary care antibiotic prescribing on incidence rates
Published in: International Journal of Clinical Pharmacy
Nov 29, 2018
The impact of an antibiotic policy on reducing high-risk antibiotic usage and on the incidence of MRSA and CDI at a teaching hospital in United Kingdom
Published in: Medication Safety Conference AbDhabi 2-4 November 2018
Nov 02, 2018
Effects of Alogliptin on hypertensive chronic kidney disease with Type 2 diabetes mellitus
Published in: Australasian medical journal
May 03, 2018
Amira Shaaban
Nadia Hussain
Farideh Javaid
Background: Diabetes mellitus(DM)is a leading cause of chronic kidney disease (CKD). Theantihyperglycemic treatment options for patients with Type 2 DM are limited because of safety and tolerability concerns. Aims: To retrospectively assess the effect of using Alogliptin; a dipeptidyl peptidase-4 inhibitor (DPP-4i) alongwith conventional gliclazide: a sulphonylurea (SU) on renal outcomes and glycaemiccontrol in T2DM patients with mildCKDand hypertens...
Assessing patient satisfaction with the Medication Management Review service delivered in Jordan
Published in: Journal of Pharmaceutical Health Services Research
Apr 30, 2018
Objective To investigate the effect of the Medication Management Review (MMR) service on the number of treatment‐related problems (TRPs), patient satisfaction and factors affecting patient satisfaction. Methods This prospective, randomized controlled trial was conducted at community pharmacies in Amman, Jordan. Eligible patients were randomized into active and control groups. A validated Pharmaceutical Care Manual was used for data collection and to identify TRPs for both groups. Identified TRP...
Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia
Published in: International Journal of Breast Cancer
Apr 19, 2018
Nadia Hussain
Amira Shaaban
Zainab Khan
Abstract Aim. To evaluate the safety issues and adverse effects of using TCHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab) versus TCP regimen (docetaxel, carboplatin, and trastuzumab) in older postmenopausal women with nonmetastatic HER2-positive breast cancer. HER2 overexpressed in 20–25% of breast cancer signals an aggressive form of breast cancer and is treated with trastuzumab and pertuzumab. Methods. The patient record database was accessed to identify all postmenopausal ...